饮食血红铁:对有效性,安全性和耐受性的审查
Douglas Kalman1,2, Susan Hewlings1, Alexis Madelyn-Adjei1,3
1Substantiation Sciences, LLC, Weston, FL 33332, USA.
Nutrients
|July 12, 2025
概括
在动物食品中发现的血红铁比非血红铁更好地吸收. 补充血红铁可以帮助对抗全球缺铁性贫血.
科学领域:
- 营养科学 营养科学
- 生物化学 生物化学
- 人体生理学 人体生理学
背景情况:
- 缺铁性贫血影响全球超过20亿人,使其成为最常见的营养素缺乏症.
- 食铁主要来自动物产品中的血红铁和植物性食品和补充剂中的非血红铁.
- 血红素铁的吸收通过肠道细胞的活性运输发生,与非血红素铁路径不同.
研究的目的:
- 审查与非黑米铁来源相比,黑米铁的独特特性.
- 探索铁补充剂在治疗缺铁性贫血方面的潜力.
- 确定未来的研究方向,以优化血铁战略.
主要方法:
- 关于血铁生物可用性和吸收机制的文献综述.
- 对血红与非血红铁吸收途径的比较分析.
- 综合当前对铁代谢和缺铁的理解.
主要成果:
- 与非血红铁相比,血红铁具有更高的生物可用性和独特的吸收机制.
- 血红铁的吸收是由肠道肠细胞内的血红氧酶促进的.
- 涉及增加血红素铁摄入量的饮食策略显示出减少缺铁的承诺.
结论:
- 黑米铁是一种高度生物可利用的铁形式,具有潜在的治疗应用.
- 有针对性的铁补充策略需要进一步研究疗效和安全性.
- 优化血红铁的吸收和肠道健康对于全球管理铁缺乏症至关重要.
相关概念视频
The Periodic Table and Organismal Elements
161.6K
OverviewElements are the smallest units of matter that cannot be broken down further by chemical processes. There are 118 known elements, but not all of these are naturally-occurring, and fewer still are essential for life. Living matter is composed primarily of carbon, nitrogen, hydrogen, and oxygen, with smaller amounts of other elements like calcium, phosphorus, potassium, and sulfur. Other elements are also necessary for life but only in trace amounts.The Periodic Table Provides Information...
161.6K
Bioavailability Study Design: Healthy Subjects Versus Patients
248
Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
248
Bioavailability Enhancement: Drug Stability Enhancement and GI Retention
332
Improving a drug's stability in the gastrointestinal (GI) tract is paramount for enhancing its bioavailability and therapeutic effectiveness. Various strategies are employed to protect the drug from the harsh gastric milieu and to ensure its release and absorption at the desired site within the GI tract.Polymer coatings are one such method used to shield drugs from the stomach's acidic environment. By preventing premature drug release, these coatings improve the bioavailability of unstable...
332
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
382
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
382
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
271
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
271
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
379
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
379


